Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Notch Pathway Implicated in Multiple Sclerosis
23 September 2002. The Notch signaling pathway is of considerable interest to those studying Alzheimer's disease because the Notch receptor and the amyloid-β precursor protein (AβPP) are proteolytically processed much the same manner. γ-Secretase cleavage of these proteins results in the release of intracellular domains (NICD and AICD) that have profound cellular consequences (see ARF related news story and ARF related news story). Researchers at the Albert Einstein College of Medicine reveal in today’s online Nature Medicine that the Notch pathway may contribute to the progression of another neurodegenerative disease, multiple sclerosis (MS).

Because inflammation and reactive astrocytes have been implicated in the etiology of MS, first author Gareth John and colleagues, working with senior author Celia Brosnan, used microarray analysis to determine what genes may be switched on or off in astrocytes in response to the inflammatory cytokines interferon-g, interleukin 1b, and transforming growth factor b1 (TGF-b1). Among many genes repressed or induced by these cytokines, the authors found that Jagged1, a Notch ligand, was induced by TGF-b1, while Delta 1, another Notch ligand, was unaffected.

This specific effect is significant in that pre-myelinating oligodendrocytes are known to express the Notch receptor, and its activation induces expression of the transcription factor Hes5, which prevents the cells from maturing into myelinating oligodendrocytes. The TGF-b1, Jagged1, Notch relay may, therefore, prevent the essential remyelination of neurons.

In support of this theory, John et al., using autopsy tissue samples, found that the main players in this path of destruction, Jagged1, Notch1, and Hes5, are all present in MS lesions. Jagged1, however, was not found in remyelinating lesions, only in demyelinating ones, as would be predicted if it played a central role in disease progression.

What all this means for Alzheimer’s disease is unclear, but recent findings of white-matter atrophy in AD suggests that demyelination may be an important event in this disease as well. In any event, the potential role of the Notch pathway in an inflammatory response in the brain, which may or may not impact neuronal repair, seems worth investigating.-Tom Fagan

Reference:
John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, Brosnan CF. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Medicine Online. 2002 September 23. (Abstract)

 
Comments on News and Primary Papers
  Comment by:  Chris Exley
Submitted 29 June 2002  |  Permalink Posted 29 June 2002

The two recent papers published in Science showing an apparent connection between A beta and tau pathologies in transgenic mice models are interesting. However, neither paper reports the effect of a positive control. In both cases a combination of two possible stressors has resulted in a final pathology that is greater than would be expected from the sum of these stressors. However, this is nothing new or even unexpected. It would be new if the resultant pathology could only be reproduced using this combination of stressors. This does not appear to have been tested. The possibility that the observed effects might be explained as a non-specific interaction between 2 co-occurring stressors would explain the lack of similarity of the resulting pathology with that observed in AD. Just a thought.

View all comments by Chris Exley
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad